NAIROBI (Reuters) – Kenya is going ahead with its plan to inoculate its citizens against COVID-19 using a vaccine developed by AstraZeneca, a senior health ministry official said on Thursday, dismissing concerns over its efficacy.
South Africa paused the rollout of the vaccine developed by AstraZeneca and Oxford University following a small clinical trial that showed it offered minimal protection against mild to moderate illness from the 501Y.V2 variant dominant in the country.
That move will not deter Kenya, which says it expects to receive 24 million doses of the vaccine beginning this month, said Mercy Mwangangi, the chief administrative secretary at the ministry.
“We are going to continue with AstraZeneca because we are doing our own sequencing and we are comfortable to move forward with it,” she told Reuters.
The World Heath Organisation had also issued an advisory on Wednesday telling countries to continue using the vaccine, Mwangangi said, which further supports the Kenyan government’s position.
more recommended stories
Tiger Woods in hospital after being pulled from car wreck with jaws of life
Golfer Tiger Woods was in hospital.
South Africa’s unemployment rate jumps to new record high
PRETORIA (Reuters) – South Africa’s unemployment.
Ugandan opposition leader Bobi Wine withdraws election petition
The Ugandan opposition leader Bobi Wine.
Zimbabwean Instagram Influencer Loloskloset Curates Viral Valentine’s Experience for Khanyi Mbau and her Zimbabwean Lover
Zimbabwean born social media influence and.
Judge seeks jail for Jacob Zuma over ‘contempt of court’
A official inquiry into “state capture”.
UK Supreme Court allows Nigerians to sue Shell in English courts: ruling
The UK Supreme Court on Friday.